Pfizer Inc. (NYSE:PFE) finished Wednesday with a subtraction of -$0.18 to close at $36.66, a downside of -0.49 percent. An average of 24,332,561 shares of common stock have been traded in the last five days. There was a gain of $1.18 in the past week, and it reached a new high 11 times over the past 12 months. The last 20 days have seen an average of 25,504,025 shares traded, while the 50-day average volume stands at 25,062,102.
PFE stock has decreased by -1.08% in the last month. The company shares reached their 1-month lowest point of $34.65 on 08/04/23. With the stock rallying to its 52-week high on 01/06/23, shares of the company touched a low of $34.65 and a high of $54.93 in 52 weeks. It has reached a new high 2 times so far this year and lost -28.45% or -$14.58 in price. In spite of this, the price is down -33.26% from the 52-week high.
Insider Transactions
PFE stock investors should be aware that Pfizer Inc. (PFE) stock had its last reported insider trading activity 162 days ago on May 08.
Valuation Metrics
Pfizer Inc. (PFE) has a trailing price-to-earnings (P/E) ratio of 9.77. The stock’s beta is 0.57. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.64, the price-to-book (PB) ratio at 2.09, and the price-to-cash flow ratio at 19.33.
The company has a payout ratio of 42.40%. The company’s most recent quarterly dividend payment was $0.41 a share, without any change from last year. Its latest increase dividend $0.01 reported on Friday December 9 2022.
Financial Health
The quick ratio of Pfizer Inc. for the three months ended June 29 was 1.80, and the current ratio was 2.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.62 and a total debt to equity ratio of 0.66 for the quarter ending June 29. Pfizer Inc.’s EBITDA margin for the year ending June 29 is 42.47%, while its operating margin for the same period stands at 29.90%. Its gross profit as reported stood at $65.99 billion compared to revenue of $100.33 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Pfizer Inc.’s return on assets was 10.60%.
Earnings Surprise
For the three-month period that ended June 29, Pfizer Inc. had $61.36 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $2.33 billion in the quarter, while revenues of $5.54 billion were shrunk -325.7%. The analyst consensus anticipated Pfizer Inc.’s latest quarter earnings to come in at $0.57 per share, but it turned out to be $0.67, a 17.50% surprise. For the quarter, EBITDA amounted to $3.49 billion. Shareholders own equity worth $5.65 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Pfizer Inc. (PFE) price momentum. RSI 9-day as of the close on 23 August was 58.35%, suggesting the stock is Neutral, with historical volatility in this time frame at 19.26%.
As of today, PFE’s price is $36.74 +3.33% or $1.18 from its 5-day moving average. PFE is currently trading -1.48% lower than its 20-day SMA and -9.21% lower than its 100-day SMA. However, the stock’s current price level is -8.12% below the SMA50 and -21.28% below the SMA200.
The stochastic %K and %D were 86.20% and 87.77%, respectively, and the average true range (ATR) was 0.76. With the 14-day stochastic at 79.22% and the average true range at 0.73, the RSI (14) stands at 54.37%. The stock has reached 0.54 on the 9-day MACD Oscillator while the 14-day reading was at 0.80.
Analyst Ratings
JP Morgan reiterated its a Neutral rating on Pfizer Inc. (NYSE: PFE), but raised their price target to $45, indicating a potential price increase of 18.53% for the stock. The consensus rating for Pfizer Inc. (PFE) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PFE, while 15 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 10 others rate it as a “buy”.
What is PFE’s price target for the next 12 months?
Analysts predict a range of price targets between $32.00 and $75.00, with a median target of $41.00. Taking a look at these predictions, the average price target given by analysts for Pfizer Inc. (PFE) stock is $44.09.
